Actual News History Analyses Other

Crucell News



profile

quote

news
-

 Thursday January 10 2002
Crucell enters into license agreement with Molelecular Medicine
Dutch antibody and vaccine company Crucell on Thursday announced that it entered into a license agreement with San Diego-based Molecular Medicine, LLC to offer manufacturing services for clinical grade materials on Crucell's proprietary PER.C6 technology in the US. Under the terms of the agreement, Crucell will receive upfront and annual payments, as well as double-digit royalties on sales.

Monday October 22 2001
Pro forma Net loss Crucell Q3 2001 EUR 3.1 mln
Dutch antibody and vaccine company Crucell saw its third quarter revenues increase by 300 % compared to the same quarter last year. Contributing to third quarter results is a deal with Johnson & Johnson to produce a promising cancer antibody. The company further obtained patent protection for its MAbstract technology and appointed two renowned scientists.

Friday September 28 2001
Crucell appoints Director of Business Development
Crucell N.V., on Friday announced that it has appointed Judith Heikoop as Director of Business Development for its human cell line business. Mrs. Heikoop will be responsible for the commercialization of Crucell's human cell line expression platform, PER.C6, as a production platform for human antibodies and therapeutic proteins.

Wednesday August 29 2001
Crucell appoints VP Corporate Development & Strategy
Crucell N.V. on Wednesday announced that it has appointed Arsia Amir-Aslani as Vice President Corporate Development & Strategy. Dr Amir-Aslani will be responsible for Crucell's investor relations and corporate marketing activities. Dr Amir-Aslani is a former investment banker and was a senior marketing and communications executive at a specialized healthcare consultancy firm, where he provided distinctive and innovative service to an array of leading US and European biotech companies.

Thursday August 16 2001
Crucell enters development & commercialization agreement with Centocor
Crucell N.V. on Thursday announced that it has entered into an agreement with Centocor,., for the development and commercialization of Crucell's CD46-specific human antibodies for the treatment of cancer. Centocor will pay Crucell upfront, annual and milestone fees until product launch, and royalties afterwards.

Tuesday July 24 2001
Net loss Crucell Q2 2001 EUR 7.1 mln
Crucell N.V. on Tuesday announced its second quarter results for 2001. Revenues for the quarter are EUR 1.2 mln (USD 1.0 mln), compared to EUR 0.6 mln (USD 0.5 mln) for the quarter ended June 30, 2000. The pro forma loss amounted to EUR 4.4 mln (USD 3.7 mln), or EUR 0.13 per share (USD 0.11), compared to EUR 2.5 mln (USD 2.1 mln) for the same period in 2000, or EUR 0.13 per share (USD 0.11).

Wednesday July 11 2001
Crucell appoints Toon Stegmann as Director of Vaccine Research
Crucell N.V. on Wednesday announced that it has appointed Dr. Toon Stegmann as Director of Vaccine Research. Dr. Stegmann is an internationally renowned expert in the field of influenza virus and HIV, his achievements include developing a methodology for the reconstitution of viral membranes. Dr. Stegmann joins Crucell after having worked for almost five years as a professor and group leader at the University, Paul Sabatier/Laboratoire de Pharmacologie et de Biologie Structurale in France.

Tuesday June 26 2001
Crucell signs licensing & production agreement with Selective Genetics
Crucell on Tuesday announced that it has signed a licensing and production agreement with San Diego (CA)-based Selective Genetics. for access to its PER.C6 tm technology and for manufacture their therapeutic product for studies in the USA. Under the terms of the agreement, Selective Genetics will receive a non-exclusive license to Crucell's PER C6 tm cell line.

Friday June 1 2001
Crucell presents Ad Vac tm, a new improved vaccine technology
Crucel N.V. on Friday presents data demonstrating that their new system for vaccination, called AdVac tm, stimulates a stronger immune response. with improved safety. The data will be presented on Friday at the 4th annual meeting of the American Society for Gene Therapy (ASGT) in Seattle, Washington.

Wednesday May 23 2001
Crucell boosts its target discovery and antibody development engine
Crucell N.V. on Wednesday announced that it has developed and rested a new, improved and larger phage antibody-display library of human antibody fragments, for target discovery and the delopment of antibody based therapeutics. This library is part of Crucell's MAbstract tm technology to discover novel targets on disease-associated cells and generate fully human monoclonal antibodies against those targets in the areas of cancer, chronic inflammation, cardiovascular disease.

Tuesday May 15 2001
Crucell and UMC Utrecht cooperate on treatment type 2 diabetes
Crucell N.V. on Tuesday announced that they have agreed with the University Medical Center Utrecht (UMC Utrecht)in the Netherlands, to cooperate to discover targets, therapeutic human antibodies and vaccines for treatment of treatment of type 2 diabetes mellitus. Type 2 diabetes is the most common form of diabetes that currently affects an estimated 120 million people worldwide.

Monday March 12 2001
Crucell: Pro Forma net loss EUR 11.2 mln
Revenues of Crucell for the the full year increased 116% to Eur 6.9 million (USD 6.4 mln), mainly consisting of license fees, compared to Eur 3.2 million (USD 2.9 mln) for the corresponding year ended December 31, 1999. In line with expectations, the pro forma loss amounted to Eur 11.2 million (USD 10.3 mln), or Eur (0.46) per share (USD 0.42), as compared to Eur 7.3 million (USD 6.8 mln) in 1999, or Eur (0.42) per share (USD 0.39).

Wednesday January 31 2001
Crucell signs production agreement with DirectGene
Crucell N.V. on Wednesday announced that it has signed a production agreement with Annapolis (USA) based DirectGene. to manufacture their therapeutic product for studies in the USA. Under the terms of the agreement, Curcell will manufacture clinical grade batches of DirectGene's product for treatment of prostate cancer using its human cell line production platform PER.C6.

Monday January 15 2001
Crucell signs licensing deal with Cell Genesys Inc.
Crucell N.V. on Monday announced that it has signed a licensing agreement with US based Cell Genesys. for access to its PER.C6 technology. Under the terms of the agreement, Cell Genesys will license Crucell's PER.C6 adenoviral packaging cell line for research purposes, with an option to convert to a commercial license within five years.

Friday December 22 2000
Nett liss Q3 2000 Crucell EUR 20.7 mln
Crucell N.V. on Friday announced its financial results for the third quarter ended September 30, 2000. Total net revenues were Eur 0.8 million (USD 0.7 mln), compared to Eur 1.4 million (USD 1.2 mln) in the third quarter of 1999. In line with expectations, this reflects the development stage of the company.

Hebels Financial Website believes the information herein was obtained from reliable sources but does not guarantee its accuracy. Neither the information nor any opinion expressed constitutes a solicitation of the purchase or sale of securities, derivatives or commodities. © 2002 Hebels Financial Website